Health
Follow-up Sinks Candesartan as Cardioprotection in Breast Cancer – Medscape
The new PRADA findings suggest cardioprotective drugs may not be necessary for all patients during adjuvant breast cancer therapy, the authors say.
After a modest early signal of benefit, candesartan cilexetil (Atacand, Cheplapharm) showed no effect on key markers of heart health 2 years after treatment in patients with early-stage breast cancer in the randomized PRADA trial.
The 2015 study was hailed at the time as the largest randomized trial in breast cancer to look at the effects of angiotensin-receptor blockade with candesartan and the -blocker metoprolol, both against placebo, on cardiac dysfunction. The 120 patients received adjuvant…
-
General12 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General12 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News21 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws
-
General12 hours agoOf saints and sinners | The Spectator Australia